濟川藥業(600566.SH):蒲地藍消炎口服液將於2022年退出新疆省級醫保目錄
格隆匯9月10日丨濟川藥業(600566.SH)公佈,根據新疆維吾爾自治區醫療保障局、新疆維吾爾自治區人力資源和社會保障廳、新疆生產建設兵團醫療保障局、新疆生產建設兵團人力資源和社會保障局印發的《關於將新疆維吾爾自治區、新疆生產建設兵團基本醫療保險、工傷保險和生育保險藥品目錄自行增補品種調出支付範圍的通知》(新醫保【2021】97號),自2022年1月1日起,將《新疆維吾爾自治區、新疆生產建設兵團基本醫療保險、工傷保險和生育保險藥品目錄》自行增補藥品中非民族藥的305個品種全部調出醫保支付範圍。公司的全資子公司濟川藥業集團有限公司主要品種蒲地藍消炎口服液在本次調出醫保支付範圍內。
蒲地藍消炎口服液將於2022年1月1日退出《新疆維吾爾自治區、新疆生產建設兵團基本醫療保險、工傷保險和生育保險藥品目錄》。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.